Back to News

Aragen Bioscience Announces the Appointment of Steven Lang, PhD, MBA as Vice President, Biologics

February 25, 2020

The addition of Dr. Lang is part of a multi-year investment in Aragen’s team, facilities and technologies.

Morgan Hill, California — February 25, 2020 — Aragen Bioscience is pleased to announce the appointment of Dr. Steven Lang as Vice President, Biologics. Aragen, a wholly-owned subsidiary of GVK BIO, is a leading Contract Research Organization focused on accelerating biologics product development with an integrated offering that includes antibody discovery and humanization, stable cell line development, recombinant protein production and purification, and differentiated diseases models.

“It’s my pleasure to welcome Dr. Steven Lang to Aragen.” said Axel Schleyer, CEO, Aragen Bioscience. “The addition of Dr. Lang is part of Aragen’s ongoing investment in our team, facilities and technologies. This multiyear expansion in our capabilities has included adding over 15,000 square feet of laboratory space, introducing our proprietary RapTr™ Cell Line Development services and adding mass spectrometry to our analytical tool set. Dr. Lang’s technical expertise in discovery and development as well as his track record in creating innovative and dynamic teams will be invaluable in building on Aragen’s growth.”

Prior to joining Aragen, Dr. Lang was with Genentech’s Cell Culture department as a Director overseeing research material generation, cell line development, automation, and CHO process development covering activities from DNA to Phase 2 clinical supplies. In addition to his functional role, he led an initiative to modernize the CMC scientific data management processes. This work spawned numerous digitization efforts across the global Roche Technical Development network to drive efficiency, transparency and compliance. He also acted as a CMC leader for a project team delivering an innovative bispecific antibody into clinical trials.

Prior to Genentech, Dr. Lang was with Janssen Research and Development where he built the analytical discovery, stability screening and cell line development groups into important interfaces between discovery and development. He brought experience in biologics discovery, technology development, process optimization, project leadership, due diligence and strategic interactions. At Johnson & Johnson, he had roles spanning preclinical, early development, regulatory filings and late-stage/marketed product support as a functional and CMC project leader.

Dr. Lang received his PhD in Molecular Microbiology from State University of New York Stony Brook. He then undertook post-doctoral work at Stony Brook and Johnson & Johnson Pharmaceutical R&D. He received his MBA from Rider University.

About Aragen Bioscience, Inc
Aragen Bioscience, Inc., a wholly owned subsidiary of GVK BIO, is a leading contract research organization based in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of In Vitro and In Vivo services for the discovery, characterization, activity assessment and early development of biologic and diagnostic products.